The Hunt for the Next 10 Bagger

[BioSpecialist]

CLSD breakouts



CLSD = Market cap $39 Mil // Cash $65 Mil //NDA acceptance IMMINENT & FDA DECISION by MID YEAR for potential Blockbuster // Shares Out 32 Mil = 15 BAGGER GEM...UNDISCOVERED Stock trading almost 40% below Cash.

https://www.barrons.com/articles/PR-CO-20181219-911604

Uveitis is a set of ocular inflammatory conditions and is one of the leading causes of vision loss, affecting about 350,000 patients in the U.S. and more than one million worldwide.

If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis. The uveitis market is expected to grow to nearly $550-million in the U.S. and more than $1-billion globally by 2024.